Tibsovo Approval Is A Stepping Stone For Servier’s Longer-Term Oncology Strategy

The privately held company expects five US FDA approvals by 2026 and will focus on big-ticket targets like immune checkpoints and cell therapies, CEO David K. Lee told Scrip.

Digital illustration of Cancer cell in colour background — • Source: Shutterstock

By itself, the US Food and Drug Administration’s approval of Tibsovo (ivosidenib) for IDH1-mutated cholangiocarcinoma is a largely incremental development for a drug already on the market for three years. But for Servier Pharmaceuticals, it marks its entry into solid tumors and an important step for a larger oncology strategy that is particularly focused on hot-topic disease targets and modalities like immune checkpoint inhibitors, biomarker-driven indications and cell therapy.

The Boston-based company, part of France-based Les Laboratoires Servier SAS, announced Tibsovo’s approval on 25 August in adults with...